Lung Cancer in Ever- and Never-Smokers: Findings from Multi-Population GWAS Studies.

"Authors' Disclosures S.M. Rosenberg reports part of this work was funded by U.S. NIH grant R01-CA250905. A. Risch reports grants from Deutsche Krebshilfe and NIH during the conduct of the study. S.M. Arnold reports other support from Merck Sharp & Dohme, AstraZeneca Pharma, Ellipses Pharma Limited, AbbVie Incorporated, LabCorp, Exelixis, Incyte Corp, Eli Lilly, Beigene, and Kinnate Biopharma Inc outside the submitted work. M.P.A. Davies reports grants from Roy Castle Lung Cancer Foundation during the conduct of the study. L. Le Marchand reports grants from NCI during the conduct of the study. M.C. Aldrich reports grants from NIH/NCI during the conduct of the study; personal fees from Guardant Health outside the submitted work. A.G. Schwartz reports grants from NIH during the conduct of the study. K.S. Purrington reports grants from NCI during the conduct of the study. S.M. Pinney reports grants from NCI and National Institute of Environmental Health Sciences during the conduct of the study. C.I. Amos reports grants from NCI during the conduct of the study. No disclosures were reported by the other authors."

"The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the NIH, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses described in this manuscript were obtained from dbGaP accession number phs000424.v7. p2. Thanks to Kathryn Edwards and Zachary Xiao for proofreading the article. The research in this study is supported by the NCI of the NIH under award numbers U19CA203654, U01CA243483, R21CA235464; by Cancer Prevention Research Institute of Texas (CPRIT) under award numbers RR170048, RR160097T, RR180061; by the Department of Health and Human Services contracts under award numbers HHSN26820100007C, HHSN268201700012C, 75N92020C00001; by NCI of the NIH under award number X01HG007491 under contract number HHSN268201200008I. The CARET study is funded by the NCI of the NIH under award numbers U01CA063673, UM1CA167462, and U01CA167462; the Harvard Lung Cancer Study is funded by the NCI of the NIH under award number U01CA209414; the Asian validation study is funded by the National Natural Science Foundation of China under award number 81820108028; the Liverpool Lung Project is supported by MPAD Roy Castle Lung Foundation (UK); the EAGLE study is supported by the intramural program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute of the NIH; the ReSoLuCENT study is funded by the Weston Park Hospital Cancer Charity. Acknowledgment to the George IsAFRc Family Fund for Cancer Research for grant support. J.E. Bailey-Wilson was supported by the Intramural Research Program of the National Human Genome Research Institute at NIH. J. Xia was supported by the National Institute of Environmental Health Sciences of the NIH under award number KK99ES033259, the Nebraska Health Care Funding Act LB692, and Cancer and Smoking Disease Research Program LB595. S.M. Rosenberg was supported by NCI of the NIH under award number R01CA250905 and by the National Institute on Aging of NIH under award number DP1AG072751. This project was also supported by the Cytometry and Cell Sorting Core at Baylor College of Medicine with funding from the CPRIT Core Facility Support under award number RP180672, the NIH under award number P30CA125123 and S10RR024574, and the assistance of Joel M Sederstrom. C.I Amos and C. Cheng are Research Scholars at the Cancer Prevention Institute of Texas."